Definium Therapeutics Inc (DFTX) Q4 2025 earnings summary

Executive summary

• Four pivotal phase III studies for DT120 ODT in GAD and MDD are progressing, with Emerge (MDD) fully enrolled and topline data expected late Q2 2026, Voyage (GAD) 80% enrolled with data in early Q3 2026, and Panorama (GAD) on track for 2H 2026.

• Initiated phase IIa study of DT-402 in autism spectrum disorder, with first participant dosed and initial data expected in 2026.

• Raised $259 million in equity financing in 4Q 2025, extending cash runway into 2028 and bringing in new institutional investors.

• Strengthened leadership team with new CFO, CCO, and expanded Board to support commercial readiness and upcoming launches.

• Published Phase 2b GAD study results in JAMA; DT120 received FDA Breakthrough Designation for GAD.

Financial highlights

• Research and development expenses rose to $117.7 million for 2025, up from $65.3 million in 2024, mainly due to higher DT120 program costs.

• General and administrative expenses increased to $48.6 million from $38.6 million year-over-year, driven by professional services, pre-commercialization, and personnel costs.

• Net loss for 2025 was $183.8 million, compared to $108.7 million in 2024, with net loss per share at $2.06 versus $1.54.

• Cash, cash equivalents, and investments at year-end 2025 were $411.6 million, up from $273.7 million at year-end 2024.

• Weighted-average shares outstanding increased to 89.3 million in 2025, up from 70.5 million in 2024.

Outlook and guidance

• Cash position expected to fund operations into 2028, supporting NDA preparation, market access, and commercial launch activities.

• Three pivotal phase III readouts anticipated in 2026: Emerge (MDD) in late Q2, Voyage (GAD) in early Q3, and Panorama (GAD) in the second half.

• First patient dosing for Ascend (Phase 3 MDD) expected by early Q2 2026.

• Continued focus on disciplined execution, capital allocation, and advancing programs for long-term value creation.